Advertisement
CRMD vs GYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Hold and GYRE is a Hold.
CRMD's RSI Indicator is remaining in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMD advanced for three days, in 230 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRMD as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CRMD turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CRMD moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CRMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRMD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (3.498). P/E Ratio (2.163) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (5.636) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.564) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
GYRE sees MACD Histogram crosses below signal line
GYRE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 37 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.498). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CRMD | GYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 96 | 98 | |
SMR RATING 1..100 | 19 | 95 | |
PRICE GROWTH RATING 1..100 | 82 | 84 | |
P/E GROWTH RATING 1..100 | 97 | 98 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GYRE's Valuation (9) in the null industry is significantly better than the same rating for CRMD (87) in the Medical Specialties industry. This means that GYRE’s stock grew significantly faster than CRMD’s over the last 12 months.
CRMD's Profit vs Risk Rating (96) in the Medical Specialties industry is in the same range as GYRE (98) in the null industry. This means that CRMD’s stock grew similarly to GYRE’s over the last 12 months.
CRMD's SMR Rating (19) in the Medical Specialties industry is significantly better than the same rating for GYRE (95) in the null industry. This means that CRMD’s stock grew significantly faster than GYRE’s over the last 12 months.
CRMD's Price Growth Rating (82) in the Medical Specialties industry is in the same range as GYRE (84) in the null industry. This means that CRMD’s stock grew similarly to GYRE’s over the last 12 months.
CRMD's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as GYRE (98) in the null industry. This means that CRMD’s stock grew similarly to GYRE’s over the last 12 months.
| CRMD | GYRE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 81% | 15 days ago 83% |
| Declines ODDS (%) | 10 days ago 85% | 2 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRMD’s FA Score shows that 1 FA rating(s) are green while GYRE’s FA Score has 1 green FA rating(s).
- CRMD’s FA Score: 1 green, 4 red.
- GYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRMD’s TA Score shows that 4 TA indicator(s) are bullish while GYRE’s TA Score has 4 bullish TA indicator(s).
- CRMD’s TA Score: 4 bullish, 6 bearish.
- GYRE’s TA Score: 4 bullish, 6 bearish.
Price Growth
CRMD (@Biotechnology) experienced а -3.42% price change this week, while GYRE (@Biotechnology) price change was -4.73% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
CRMD is expected to report earnings on Nov 12, 2026.
GYRE is expected to report earnings on Mar 30, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CRMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with IMRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To CRMD | 1D Price Change % | ||
|---|---|---|---|---|
| CRMD | 100% | -1.83% | ||
| IMRX - CRMD | 48% Loosely correlated | +5.48% | ||
| ABOS - CRMD | 45% Loosely correlated | -2.95% | ||
| ACRV - CRMD | 43% Loosely correlated | -0.63% | ||
| GYRE - CRMD | 36% Loosely correlated | -9.03% | ||
| PMN - CRMD | 35% Loosely correlated | -1.73% | ||
More | ||||
GYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with ABOS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then ABOS could also see price increases.
| Ticker / NAME | Correlation To GYRE | 1D Price Change % | ||
|---|---|---|---|---|
| GYRE | 100% | -9.03% | ||
| ABOS - GYRE | 53% Loosely correlated | -2.95% | ||
| PMN - GYRE | 44% Loosely correlated | -1.73% | ||
| PTHS - GYRE | 41% Loosely correlated | -5.02% | ||
| CRSP - GYRE | 39% Loosely correlated | -9.77% | ||
| SPRC - GYRE | 38% Loosely correlated | -8.78% | ||
More | ||||